Lineage Cell Therapeutics, Inc. Convertible Notes Payable, Current
Lineage Cell Therapeutics, Inc. (LCTX) had Convertible Notes Payable, Current of $13.00 thousand as of 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current › Notes and Loans Payable, Current › Notes Payable, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2018-03-15
- 2017-09-30: Convertible Notes Payable, Current $13.00K.
- 2017-06-30: Convertible Notes Payable, Current $2.56M.
- 2017-03-31: Convertible Notes Payable, Current $1.07M.
- 2016-12-31: Convertible Notes Payable, Current $833.00K.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2017-09-30 | $13.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $2.56M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.07M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $833.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | $357.00K 10-Q · filed 2016-11-04 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 |
| 2015-09-30 | $255.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $238.00K 10-Q · filed 2015-08-10 |
| 2014-12-31 | $60.00K 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |